EDAP TMS S.A. (EDAP) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
EDAP TMS S.A. has reported significant revenue growth for Q4 and the full year of 2023, with a standout 24.8% increase in Q4 and a strong performance in the HIFU business, buoyed by robust procedure growth in the U.S. The company, a leader in robotic energy-based therapies, anticipates further adoption of its Focal One technology and has received FDA Breakthrough Device designation for treating deep infiltrating endometriosis, signaling a promising outlook for 2024.
For further insights into EDAP stock, check out TipRanks’ Stock Analysis page.